The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G.
 
Naotoshi Sugimoto
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Daisuke Sakai
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takao Tamura
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomohiro Nishina
No Relationships to Disclose
 
Taito Esaki
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Tadamichi Denda
Research Funding - Sanofi (Inst)
 
Masahiro Tsuda
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Akitaka Makiyama
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Ayumu Hosokawa
Research Funding - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
 
Takashi Tsuda
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst)
 
Junji Kishimoto
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Ichinosuke Hyodo
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha